

			Quarter ended		Year ended	
SI.	Particulars	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
No.		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Segment wise revenue and results					
	Segment revenue					
	a) Pharmaceutical Services and Active Ingredients	6,268	5,605	5,786	22,741	22,564
	b) Global Generics	20,068	20,929	18,814	76,150	80,277
	c) Proprietary Products	27	26	417	109	417
	Total	26,363	26,560	25,017	99,000	103,258
	Less: Inter-segment revenue	1,440	1,330	1,422	5,407	6,066
	Add: Other un-allocable income			6	-	6
	Total revenue from operations	24,923	25,230	23,601	93,593	97,198
2	Segment results					
	Profit / (loss) before tax and interest from each segment					
	a) Pharmaceutical Services and Active Ingredients	383	56	(598)	(3)	(1,446)
	b) Global Generics	3,482	3,828	1,795	11,956	17,817
	c) Proprietary Products	(841)	(701)	(679)	(3,464)	(3,124)
	Total	3,024	3,183	518	8,489	13,247
	Less: (i) Finance costs	140	133	158	628	572
	(ii) Other un-allocable expenditure / (income), net	929	(666)	(1,274)	891	(2,770)
	Total profit before tax	1,955	3,716	1,634	6,970	15,445